Compare Sibanye Stillwater Ltd (SBSW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs 10X Genomics Inc — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and 10X Genomics Inc for 91 Days on average.
| SBSW | TXG | |
|---|---|---|
Market Cap | $6.88B | $10.07B |
Volume | 4,474,536 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $97.74 |
52-Week Low | $8.00 | $11.48 |
Typical Hold Time | 51 Days | 91 Days |
Enterprise Value | $7.78B | $9.59B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.91, up 2.38% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% EBITDA increase, driving positive sentiment.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying 44% upside, supported by operational improvements and commodity price strength. Risks include volatile earnings, high debt levels, and exposure to commodity cycles. Upside hinges on sustained execution of the growth roadmap and cost discipline.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
